US EditionAROA Biosurgery Completes Randomised Controlled Trial for Symphony™; Preliminary Read-Out indicates Primary Endpoint Met
Preliminary data shows Symphony healed more diabetic foot ulcers than standard care in a 12-week trial involving up to 150 patients, supporting clinical adoption efforts.
- On Sunday, March 29, 2026, Aroa Biosurgery Limited announced its randomised controlled trial for Symphony met the primary endpoint in treating diabetic foot ulcers.
- This prospective, multi-centre trial evaluated the safety and performance of Symphony in treating chronic Wagner grade 1 and 2 non-healing diabetic foot ulcers across the United States.
- Study protocols involved recruiting up to 150 patients randomised to receive either Symphony or standard of care dressings on a weekly basis for up to 12 weeks.
- Chief Executive Officer Brian Ward stated this builds the clinical evidence base for Symphony, supporting future clinical adoption and reimbursement policies for the company.
- Encouraged by the preliminary study read-out, the company looks forward to publishing full study results in the coming months to further validate Symphony's clinical efficacy.
12 Articles
12 Articles
The Times of Northwest Indiana
AROA Biosurgery Completes Randomised Controlled Trial for Symphony™; Preliminary Read-Out indicates Primary Endpoint Met
AUCKLAND, New Zealand, March 29, 2026 /PRNewswire/ -- Aroa Biosurgery Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a preliminary study read-out indicating the trial achieved its primary endpoint.
Aroa’s Symphony hits the right notes in diabetic foot ulcer trial
Aroa’s Symphony randomised controlled trial in diabetic foot ulcers completed Preliminary findings indicate the trial met its primary endpoint, outperforming standard of care Publication of the study expected to support Symphony’s clinical adoption and future US reimbursement requirements Special Report: Aroa Biosurgery has reached a key milestone, with its Symphony randomised controlled trial in diabetic foot ulcers (DFUs) now complete and p…
Coverage Details
Bias Distribution
- 56% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
